Sanofi-Aventis' Acomplia Approved

France's Sanofi-Aventis has announced that Mexico's market regulator, COFEPRIS, has approved its novel obesity treatment Acomplia (rimonabant). The development cements the Mexican drug agency's reputation for approving breakthrough drugs ahead of counterparts in the US and Latin America. However, it remains to be seen how large the local marketplace for Sanofi-Aventis' new drug will

To read the full article, please choose one of the following options: